Herbs (Global Traditional) · African
Ageratum conyzoides
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Ageratum conyzoides is a traditional African medicinal plant containing alkaloids and flavonoids that inhibit 5-alpha-reductase enzyme activity. Clinical evidence demonstrates its effectiveness in reducing benign prostatic hypertrophy symptoms and supporting prostate health.
Ageratum conyzoides is an annual herbaceous plant native to tropical and subtropical regions of Asia, Africa, and South America, belonging to the Asteraceae family. It is typically harvested as whole plant material and processed into ethanolic extracts containing alkaloids, flavonoids, terpenes, and polymethoxyflavones like 5′-methoxynobiletin.
The primary clinical evidence comes from a double-blind, randomized, placebo-controlled trial (PMID: 29048765) involving 109 men aged 41-76 with BPH, testing 250 mg/day of A. conyzoides extract for 12 weeks. This trial demonstrated significant reductions in International Prostate Symptom Score and urinary frequency without affecting hormones, PSA, or sexual function. Human clinical data is limited to this single BPH trial, with additional support from preclinical studies.
Clinically studied dosage: 250 mg/day of ethanolic extract (once daily) for 12 weeks for BPH symptoms. Animal studies used 20-100 mg/kg daily. Topical preparations: 2.5-4% extract in gel formulations. Consult a healthcare provider before starting any new supplement.
Ageratum conyzoides (Billy Goat Weed) contains a diverse array of bioactive phytochemicals rather than significant macronutrient content, as it is used medicinally rather than as a staple food. Proximate composition of dried leaf material includes crude protein approximately 12–15% dry weight, crude fiber 18–22% dry weight, ash content 8–10% dry weight, and moisture content 70–75% in fresh material. Fat content is low at approximately 2–4% dry weight. Key bioactive compounds include: (1) Flavonoids — quercetin, kaempferol, and ageconyflavone A and B, with total flavonoid content reported at 15–30 mg/g dry extract; (2) Alkaloids — pyrrolizidine alkaloids including lycopsamine and echinatine (present at trace to low concentrations, caution warranted for prolonged use); (3) Terpenoids — precocene I and precocene II (chromene compounds), β-caryophyllene, and germacrene D, collectively comprising a significant portion of the essential oil (0.1–0.5% v/w of fresh plant); (4) Phenolic acids — caffeic acid, chlorogenic acid, and ferulic acid at approximately 5–12 mg/g dry weight total; (5) Coumarins — including coumarin derivatives contributing to anticoagulant-adjacent activity; (6) Sterols — β-sitosterol identified as a primary sterol, likely contributing to 5-alpha-reductase inhibitory activity relevant to BPH management; (7) Tannins — hydrolyzable and condensed tannins at approximately 3–7% dry weight, contributing astringent and wound-healing properties. Mineral content includes potassium (~18–25 mg/g dry weight), calcium (~12–18 mg/g dry weight), magnesium (~4–6 mg/g dry weight), iron (~0.3–0.5 mg/g dry weight), and zinc (~0.05–0.1 mg/g dry weight). Vitamin content is modest; ascorbic acid (Vitamin C) is present at approximately 20–40 mg/100g fresh weight. Bioavailability notes: phenolic compounds show moderate bioavailability enhanced by aqueous extraction (consistent with traditional water extract preparations); β-sitosterol has inherently low intestinal absorption (~5%), which is typical of plant sterols; pyrrolizidine alkaloids are hepatotoxic at cumulative doses and bioavailability increases with prolonged oral use, warranting caution; essential oil volatile compounds are best delivered via topical or inhalation routes for wound-healing applications.
Ageratum conyzoides contains pyrrolizidine alkaloids and flavonoids that selectively inhibit 5-alpha-reductase type II enzyme, reducing dihydrotestosterone (DHT) conversion from testosterone. This mechanism has been demonstrated in human prostate epithelial cell cultures, leading to decreased prostatic cell proliferation and inflammation markers.
One randomized controlled trial with 109 participants demonstrated significant improvements in International Prostate Symptom Score (IPSS) and reduced urinary frequency in men with benign prostatic hypertrophy. The study showed statistically significant benefits compared to placebo over 12 weeks of treatment. However, clinical evidence remains limited to this single human trial, with traditional use primarily supported by ethnobotanical studies. Additional research is needed to establish optimal dosing protocols and long-term safety profiles.
Ageratum conyzoides contains pyrrolizidine alkaloids which may cause hepatotoxicity with prolonged use or high doses. The plant may interact with anticoagulant medications due to its coumarin content, potentially increasing bleeding risk. Contraindicated during pregnancy and lactation due to alkaloid content and lack of safety data. Individuals with liver disease should avoid use, and regular liver function monitoring is recommended during extended supplementation.
